Core B will provide a constant resource of mice harboring melanomas that express BRAF*, including pairs of tumor biopsies that are sensitive or resistant to BRAFi. The integrative power of this core lies in interacting and intersecting with parallel samples from human melanomas in Core A, providing cross-species triangulation of genetic elements that confer tumor microenvironment-specific phenotypic effects. This core will provide not only a bank of Braf* mouse (iBIP and M3) melanoma tissues and derivative cell lines collected at baseline, post-treatment and upon relapse, but also capability to engineer new alleles ex vivo and perform preclinical therapeutic studies. The immunocompetent background and natural tumor microenvironment setting of IBIP melanomas bring a key feature to this TMEN center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163125-04
Application #
8744892
Study Section
Special Emphasis Panel (ZCA1-SRLB-3)
Project Start
2014-08-01
Project End
2016-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
$91,116
Indirect Cost
$13,680
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Juneja, Vikram R; McGuire, Kathleen A; Manguso, Robert T et al. (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214:895-904
Smith, Michael P; Rowling, Emily J; Miskolczi, Zsofia et al. (2017) Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. EMBO Mol Med 9:1011-1029
Kwong, Lawrence N; Zou, Lihua; Chagani, Sharmeen et al. (2017) Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep 19:1304-1312
Roh, Whijae; Chen, Pei-Ling; Reuben, Alexandre et al. (2017) Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med 9:
Reuben, Alexandre; Spencer, Christine N; Prieto, Peter A et al. (2017) Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom Med 2:
Young, Helen L; Rowling, Emily J; Bugatti, Mattia et al. (2017) An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J Exp Med 214:1691-1710
Friedman, Adam A; Xia, Yun; Trippa, Lorenzo et al. (2017) Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clin Cancer Res 23:4680-4692
Tung, Nadine; Garber, Judy E; Hacker, Michele R et al. (2016) Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer. NPJ Breast Cancer 2:16002
Xu, Jie; Sun, Heather H; Fletcher, Christopher D M et al. (2016) Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol 40:443-53
Chen, Pei-Ling; Roh, Whijae; Reuben, Alexandre et al. (2016) Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6:827-37

Showing the most recent 10 out of 38 publications